10% owner New Enterprise Associates 16, L.P. buys 554,250 shares of MRKR at $3.20; +51.7% increase to 1,625,678 shares
New Enterprise Associates 16, L.P., a 10% owner of Marker Therapeutics, increased its stake by 554,250 shares to 1,625,678 shares at $3.20 per share on 2024-12-23, representing a 51.7% increase from its prior 1,071,428 shares. This is a material accumulation at a price that is -42.6% from the 52-week high of $5.96, coinciding with a period of near-term positive momentum (the stock is up 10.3% over the prior 30 days and 28.6% over 90 days). The context reveals a company under financial stress: Marker Therapeutics reported revenue of $1,926,020.00 for the latest quarter with a net loss of $2,308,192.00, annual revenue declining 63.3% year-over-year, and unprofitable full-year results, producing a $30.5M market cap. The material purchase by a major shareholder while the stock recovers from a depressed level warrants investor attention to whether the investor sees value inflection ahead or is simply managing portfolio exposure at a reduced entry point.